Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus- associated cryoglobulinemic vasculitis

Clinical and Experimental Rheumatology

Volumn 18, Issue 3, 2000, Pages 319-325

  Lamprecht, P ^a   Moosig, F ^a   Gause, A ^a   Herlyn, K ^a   Gross, W L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BVAS; C3c; Cryoglobulinemic vasculitis; DEI; Hepatitis C virus infection

Indexed keywords

COMPLEMENT COMPONENT C3C; CYCLOPHOSPHAMIDE; RECOMBINANT ALPHA2B INTERFERON; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CRYOGLOBULINEMIA; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; VASCULITIS;

ADULT; AGED; ANTIVIRAL AGENTS; COMPLEMENT C3C; CRYOGLOBULINEMIA; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULITIS;

EID: 0034118560     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. JENNETTE JC, FALK RJ, ANDRASSY K, et al.: Nomenclature of systemic vasculitides. Proposal of an international conference. Arthritis Rheum 1994; 37: 187-92.
2. GUILLEVIN L, LHOTE F, GHERARDI R: The spectrum and treatment of virus-associated vasculitides. Curr Opin Rheumalol 1997; 9: 31-6.
3. AGNELLO V: Mixed cryoglobulinemia after hepatitis C virus: More and less ambiguity. Ann Rheum Dis 1998; 57: 701-2.
4. BACON PA, MOOTS RJ, EXLEY A, LUQMANI R, RASMUSSEN N: Vital assessment of vasculitis. Clin Exp Rheumatol 1995; 13: 275-8.
5. DEREMEE RA, MCDONALD TJ, HARRISON EG, COLES DT: Wegener's granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 1976; 51: 777-81
6. REINHOLD-KELLER E, KEKOW J, SCHNABEL A, et al.: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994; 37: 919-24.
7. DEGROOT K, GROSS WL: Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus 1998; 7: 285-91.
8. SAVAGE COS, HARPER L, ADU D: Primary systemic vasculitis. Lancet 1997; 349: 553-7.
9. MONTI G, GALLI M, INVERNIZZI F et al.: Cryoglobulinemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. Q J Med 1995; 88: 115-26.
10. FERRI C, MARZO E, LONGOMBARDO G et at.: Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132-6.
11. PIETROGRANDE M, CORONA M, MILANI S, ROSTI A, RAMELLA M, TORDATO G: Relationship between rheumatoid factor and the immune response against hepatits C virus in essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13(Suppl. 13): S109-13.
12. PIOTELLI P, MALDIFASSI P, VACCA A, et al.: GISC protocol experience in the treatment of essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13(Suppl. 13): S187-90.
13. HARTMANN H, SCHOTT P, POLZIEN F, et al.: Cryoglobulinemia in chronic hepatitis C infection: Prevalence, clinical manifestations, response to interferon treatment and analysis of cryopreciptates. Z Gastroenterol 1995; 33: 643-50.
14. WANG G, HANSEN H, TATSIS E, et al.: High levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517-23.
15. HAGEN EC, DAHA MR, HERMANS J, et al.: Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53: 743-53.
16. BROUET JC, CLAUVEL JP, DANON F, et al.: Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57: 775-88.
17. MISIANI R, BELLAVITA P: Mixed cryoglobulinemia. A guide to drug treatment. Clin Immunother 1996; 5: 115-21.
18. D'AMICO G: Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650-71.
19. LAMPRECHT P, SCHNABEL A, GROSS WL: Hepatitis C Virus assoziierte kryoglobulinämische Vaskulitis. Pathophysiologie, Diagnostik und Therapie. Dtsch Med Wschr 1998; 123: 637-42.
20. GROSS WL: Systemic necrotizing vasculitis. Bailliere's Clin Rheumatol 1997; 11: 233-58.
21. SHARARA AI, HUNT CM, HAMILTON D: Hepatitic C. Ann Intern Med 1996; 125: 658-68.
22. MIGLIARESI, TIRRI G: Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl. 13): S175-80.
23. FERRI C, LA CIVITA L, CIRAFISI C et al.: Peripheral neuropathy in mixed cryoglobulinemia: Clinical and electrophysiologic investigations. J Rheumatol 1992; 19: 889-95.
24. HAYDAY RP, PATARROOYO DE ROYAS M, GIGLI IA: A newly described control mechanism of the complement activation in patients with mixed cryoglobulinemia (cryoglobulins and complement). J Invest Dermatol 1980; 74: 328-33.
25. BECKHAM JC, CALDWELL DS, PETERSON BL et al.: Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992; 12: 353-61.
26. DAMMACCO F, SANSONNO D, HAN JH et al.: Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long term, randomized, controlled study. Blood 1994; 84: 3336-43.
27. MISIANI R, BELLAVITA P, FENILI D et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
28. MAZZARO C, LACCHIN T, MORETTI M et al.: Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl. 13): S181-5.
29. AGNELLO V, CHUNG RT, KAPLAN LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-95.
30. MCHUTCHINSON JG, WILKES LB, POCKROS PJ: Pulse corticosteroid therapy increases viremia (HCV-RNA) in patients with chronic HCV infection (abstract). Hepatology 1993; 18: 87A.